ストックスクリーナーアプリを入手
22.94
2.67%
-0.63
前日終値:
$23.57
開ける：
$23.4
24時間の取引高:
1.04M
Relative Volume:
0.81
時価総額：
$2.43B
収益：
-
当期純損益:
$-150.70M
株価収益率:
-14.80
EPS:
-1.55
ネットキャッシュフロー:
$-125.67M
1週間 パフォーマンス:
-6.52%
1か月 パフォーマンス:
-2.76%
6か月 パフォーマンス:
+76.06%
1年 パフォーマンス:
-13.63%
1日の値動き範囲:
$22.78
$23.96
1週間の範囲:
$22.78
$25.08
52週間の値動き範囲:
$10.60
$30.48
Edgewise Therapeutics Inc Stock (EWTX) Company Profile
EWTX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
EWTX
Edgewise Therapeutics Inc
|
22.94 | 2.50B | 0 | -150.70M | -125.67M | -1.55 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.38 | 113.87B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.54 | 80.22B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
406.40 | 52.56B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
803.74 | 49.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.07 | 37.37B | 447.02M | -1.18B | -906.14M | -6.1812 |
Edgewise Therapeutics Inc Stock (EWTX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-09-25 | 開始されました | Goldman | Neutral |
| 2025-07-30 | 開始されました | Raymond James | Strong Buy |
| 2025-06-30 | 開始されました | H.C. Wainwright | Buy |
| 2025-04-30 | 開始されました | Guggenheim | Buy |
| 2025-04-02 | ダウングレード | Scotiabank | Sector Outperform → Sector Perform |
| 2025-03-07 | 開始されました | Scotiabank | Sector Outperform |
| 2025-01-22 | 開始されました | Stifel | Hold |
| 2024-11-22 | 開始されました | Evercore ISI | Outperform |
| 2024-03-07 | 開始されました | Piper Sandler | Overweight |
| 2023-05-01 | 開始されました | Truist | Buy |
| 2022-08-25 | ダウングレード | Goldman | Neutral → Sell |
| 2022-04-13 | 開始されました | RBC Capital Mkts | Outperform |
| 2022-01-28 | 開始されました | Goldman | Neutral |
すべてを表示
Edgewise Therapeutics Inc (EWTX) 最新ニュース
Edgewise Therapeutics CEO to outline 2026 goals at JPMorgan event - Traders Union
Edgewise Therapeutics, Inc. (EWTX) Stock Analysis: Exploring a 61.93% Upside Potential in Biotech - DirectorsTalk Interviews
Edgewise Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026 - PR Newswire
Edgewise Therapeutics reports inducement grants as permitted by the Nasdaq Listing Rules - marketscreener.com
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules - PR Newswire
H.C. Wainwright Maintains a Buy on Edgewise Therapeutics (EWTX), Sets a $42 PT - MSN
Aug Ideas: Can Edgewise Therapeutics Inc stock hit record highs againWeekly Investment Report & Momentum Based Trading Signals - moha.gov.vn
Why Edgewise Therapeutics stock rocked the market today - MSN
Edgewise Therapeutics (EWTX) Stock News, Forecasts and Analysis: What’s Driving the December 2025 Move and What Comes Next - ts2.tech
Edgewise Therapeutics (EWTX) Stock: Latest News, Analyst Forecasts, and What’s Driving the December 2025 Surge - ts2.tech
Edgewise rises on mid-stage trial data for heart disease therapy - MSN
Edgewise Therapeutics stock steady midday after $3 million insider sale filing — what’s next for EWTX - ts2.tech
Edgewise Therapeutics (NASDAQ:EWTX) Shares Gap DownHere's What Happened - MarketBeat
Analysts Are Bullish on These Healthcare Stocks: Vertex Pharmaceuticals (VRTX), Edgewise Therapeutics (EWTX) - The Globe and Mail
Valuation Update: Is Edgewise Therapeutics Inc stock a top pick in earnings seasonMarket Trend Report & Verified Entry Point Detection - moha.gov.vn
This Biotech Fund Exited an $8 Million Edgewise Stake as the Stock Slid Double Digits - The Globe and Mail
Edgewise: Maintaining Buy On Part D EDG-7500 Data And Next Q2 2026 Catalyst (NASDAQ:EWTX) - Seeking Alpha
What drives Edgewise Therapeutics Inc stock priceHigh Dividend Yield Stocks & Free Trading Signals to Sharpen Your Edge - earlytimes.in
HC Wainwright says Edgewise data reinforces EDG-7500 potential differentiation - MSN
Edgewise Therapeutics (NASDAQ:EWTX) Cut to Sell at Wall Street Zen - MarketBeat
Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Edgewise Therapeutics (EWTX) Stock Today: EDG-7500 Safety Update, Analyst Targets, and What Investors Are Watching Next - ts2.tech
Edgewise Therapeutics (NASDAQ:EWTX) Trading Down 5.2%Here's Why - MarketBeat
Edgewise Therapeutics (EWTX) Stock Surges on EDG-7500 Safety Update as Wall Street Prepares to Reopen After Christmas - ts2.tech
Medpace and Edgewise Therapeutics Advance Becker Muscular Dystrophy Study - MSN
Edgewise Therapeutics Announces Completion of the EDG-7500 CIRRUS-HCM Phase 2 Parts B and C and Favorable Interim Safety Results from the Ongoing Part D Study in Hypertrophic Cardiomyopathy - BioSpace
Edgewise Therapeutics Stock Jumps After Trial Update For Genetic Heart Disease — Wall Street Eyes A Potential Standout - Stocktwits
Edgewise Therapeutics (EWTX): Assessing Valuation After an 80% Three-Month Surge in the Share Price - Yahoo Finance
Edgewise Stock (+26%): Phase 2 HCM Safety Data Forces a Re-Rate - Trefis
Why Edgewise Therapeutics Stock Rocked the Market Today - Finviz
Why Edgewise Therapeutics Stock Rocked the Market Today - The Motley Fool
Edgewise Therapeutics: Differentiated EDG-7500 Profile, Late-Stage Cardiology Catalyst, and Expanding Pipeline Support Buy Rating - TipRanks
Edgewise Therapeutics Stock (EWTX) Jumps on EDG-7500 CIRRUS-HCM Update: Dec. 24, 2025 News, Analyst Forecasts, and Key Catalysts - ts2.tech
Edgewise Therapeutics (NASDAQ:EWTX) Shares Gap UpHere's What Happened - MarketBeat
Edgewise Therapeutics rises on positive safety data from heart disease drug trial - TradingView — Track All Markets
Edgewise posts trial data for heart disease drug (EWTX:NASDAQ) - Seeking Alpha
Edgewise Therapeutics Shares Rise After Advancing Phase 2 Hypertrophic Cardiomyopathy Trial - marketscreener.com
Why Is Edgewise Therapeutics Stock Soaring Wednesday?Edgewise Therapeutics (NASDAQ:EWTX) - Benzinga
Edgewise reports positive interim safety data for HCM drug EDG-7500 - Investing.com Nigeria
Edgewise Therapeutics stock rises on positive HCM drug update By Investing.com - Investing.com Nigeria
Edgewise Therapeutics stock rises on positive HCM drug update - Investing.com
Edgewise Therapeutics Announces Completion of the EDG-7500 CIRRU - GuruFocus
Edgewise Completed Phase 2 CIRRUS-HCM Parts B And C, Reports Favorable Interim Safety From Part D - Nasdaq
Edgewise Therapeutics Completes Parts B and C of Phase 2 Hypertrophic Cardiomyopathy Trial - marketscreener.com
Edgewise reports positive interim safety data for HCM drug EDG-7500 By Investing.com - Investing.com South Africa
Edgewise Therapeutics Inc (EWTX) 財務データ
収益
当期純利益
現金流量
EPS
2.52%
0.07%
大文字化:
|
ボリューム (24 時間):